AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol (December 27, 2007). doi:10.1152/ajplung.00333.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/5/L891    most recent
00333.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milam, J. E
Right arrow Articles by Reddy, R. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milam, J. E
Right arrow Articles by Reddy, R. C
Submitted on August 19, 2007
Accepted on December 26, 2007

PPAR-{gamma} Agonists Inhibit Pro-Fibrotic Phenotypes in Human Lung Fibroblasts and Bleomycin-Induced Pulmonary Fibrosis

Jami E Milam1, Venkat G. Keshamouni1, Sem H. Phan2, Biao Hu3, Srinivasa R Gangireddy1, Cory M. Hogaboam3, Theodore J Standiford1, Victor J. Thannickal1, and Raju C Reddy1*

1 Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, United States
2 Department of Pathology, University of Michigan, Ann Arbor, Michigan, United States; , Michigan, United States
3 Department of Pathology, University of Michigan, Ann Arbor, Michigan, United States

* To whom correspondence should be addressed. E-mail: rajuc{at}umich.edu.

Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this condition are largely ineffective. Peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) is a member of the nuclear hormone receptor superfamily whose activation produces a number of biological effects including alterations in metabolic and inflammatory responses. The role of PPAR-{gamma} as a potential therapeutic target for fibrotic lung diseases remains undefined. In this study, we show that both normal human lung fibroblasts and those obtained from patients with idiopathic interstitial pneumonias (IIPs) express PPAR-{gamma}. Treatment of lung fibroblasts and myofibroblasts with PPAR-{gamma} agonists results in inhibition of proliferative responses and induces cell cycle arrest. In addition, PPAR-{gamma} agonists, including a constitutively active PPAR-{gamma} construct (VP16-PPAR-{gamma}), inhibit the ability of transforming growth factor (TGF)-{beta}1 to induce myofibroblast differentiation and collagen secretion. PPAR-{gamma} agonists also inhibit fibrosis in a murine model even when administration is delayed until after the initial inflammation has largely resolved. These observations indicate that PPAR-{gamma} is an important regulator of fibroblast/myofibroblast activation and suggest a role for PPAR-{gamma} ligands as novel therapeutic agents for fibrotic lung diseases.




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
P. J. Barnes
Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities
Proceedings of the ATS, December 1, 2008; 5(8): 857 - 864.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. G. Belvisi and D. J. Hele
Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease
Chest, July 1, 2008; 134(1): 152 - 157.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.